The golden hour of prehospital reperfusion with triple antiplatelet therapy: A sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy

• Published in: The American heart journal Vol. 160; no. 6; pp. 1079 - 1084
• Main Authors: Heestermans, Ton, MD, PhD, van 't Hof, Arnoud W.J., MD, PhD, ten Berg, Jurriën M., MD, PhD, van Werkum, Jochem W., MD, PhD, Boersma, Eric, MSc, PhD, Mosterd, Arend, MD, PhD, Stella, Pieter R., MD, PhD, van Zoelen, Arthur B., MD, Gosselink, A.T. Marcel, MD, PhD, Kochman, Waclav, MD, PhD, Dill, Thorsten, MD, PhD, Koopmans, Petra C., PhD, van Houwelingen, Gert, MD, Zijlstra, Felix, MD, PhD, Hamm, Christian, MD, PhD
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.12.2010; Mosby; Elsevier Limited
• Subjects: Adult; Aged; Aged, 80 and over; Biological and medical sciences; Body mass index; Cardiology. Vascular system; Cardiovascular; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emergency Medical Services - methods; Female; Follow-Up Studies; Heart attacks; Humans; Infusions, Intravenous; Male; Medical imaging; Medical sciences; Middle Aged; Myocardial Infarction - physiopathology; Myocardial Infarction - therapy; Platelet Aggregation Inhibitors - administration & dosage; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors; Time Factors; Treatment Outcome; Tyrosine - administration & dosage; Tyrosine - analogs & derivatives; Young Adult; Evaluation; Drug combination; Cardiovascular disease; Time; Antiplatelet agent; Chemotherapy; Treatment; Reperfusion; Tirofiban; Analysis; Myocardium; Early; Circulatory system; Cardiology; Initiation
• ISSN: 0002-8703; 1097-6744
• DOI: 10.1016/j.ahj.2010.08.039

Background It is known that the efficacy of thrombolytic therapy in ST-segment elevation myocardial infarction (STEMI) is highly time dependent with the best efficacy when given within the so-called golden hour. This analysis from the On-TIME 2 trial evaluated the efficacy of triple antiplatelet therapy on initial patency and ST-segment resolution (STR) in relation to time from symptom onset to first medical contact. Methods The On-TIME 2 trial included 1,398 consecutive STEMI patients referred for primary percutaneous coronary intervention (PCI). Patients were randomized to dual (500 mg aspirin and 600 mg clopidogrel) or triple antiplatelet (500 mg aspirin, 600 mg clopidogrel, and tirofiban 25 μg/kg bolus and 0.15 μg/kg per minute maintenance infusion for 18 hours) pretreatment in the ambulance. Primary outcome of this sub-analysis was initial patency of the infarct-related vessel and STR before PCI according to time from symptom onset to first medical contact in quartiles. In addition, the incidence of aborted myocardial infarction, defined as the absence of a rise in creatinine kinase, was assessed. Results Initial patency, STR before PCI, and the incidence of aborted myocardial infarction gradually increased with shorter time from symptom onset to first medical contact. Initial Thrombolysis in Myocardial Infarction flow was present in 21.2% in the total population and 26.2%, 21.5%, 18.1%, and 18.8% in the time quartiles, respectively ( P for trend = .01). The incidence of complete STR pre-angiography was 16.6% in the total population and 23.4%, 18.2%, 14.7%, and 9.9% in the 4 quartiles, respectively ( P for trend < .001). This was largely driven by the effect of triple antiplatelet therapy, which further improved initial patency and STR and led to a significantly higher incidence of aborted myocardial infarction (13.2% vs 8.7%, P = .011), especially in the patients with short duration of symptoms. Conclusion Antiplatelet pretreatment before primary PCI, including a glycoprotein IIb/IIIa blocker, seems to be most effective when given shortly after symptom onset. Further studies should be performed to test this hypothesis.